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Plasmacytomas can be induced with high frequency in BALB/cAn 7r mice by 
the intraperitoneal injection of mineral oils  (1),  defined alkanes, e.g., pristane 
(2,6,10,14-tetramethylpentadecane) (2),  or  the  implantation  of plastic  Lucite 
discs (3). Histological studies (4) of mineral oil- or pristane-induced plasmacytoma 
development have provided evidence that the tumors develop in the peritoneal 
inflammatory tissue  (oil  granuloma)  that  forms  in  response  to  the  oil.  The 
intraperitoneal transplantation of plasmacytomas derived from primary hosts to 
syngeneic hosts requires conditioning of the peritoneum by pristane (5, 6). This 
phase of plasmacytoma growth appears to depend upon factors supplied by the 
oil-induced inflammatory cells (6); however, this dependence is soon lost, since 
subsequent transfers grow independently. The close association of the developing 
plasmacytoma with the oil granulomatous process also suggests that inflammatory 
cells and their products play an important role in earlier steps in the evolution 
of plasmacytomas. Support for this notion comes from the data of Takakura et 
al. (7),  who demonstrated that hydrocortisone administered chronically during 
the latent period of plasmacytoma development inhibited plasmacytomagenesis. 
Moreover, Cancro and Potter (6) found that hydrocortisone blocked the devel- 
opment  of oil  granuloma  formation  and  greatly  reduced  the  ability  of the 
pristane-treated peritoneal tissues to support the growth of transplanted primary 
plasmacytomas. In the present study we have examined the effect of the nonste- 
roidal antiinflammatory drug (NSAID),I indomethacin, on plasmacytomagenesis. 
Indomethacin  is  not  toxic  and  can  be  administered  in  the  drinking  water 
throughout  the  induction  period  (i.e.,  300  d),  thus  providing  a  system  for 
studying long-term  effects of the  drug.  This  paper  will  describe a  dramatic 
inhibition  of plasma cell tumor development in pristane-injected mice treated 
with indomethacin, and further demonstrate that indomethacin does not inhibit 
the  formation  of  the  oil  granulomatous  tissue  during  the  latent  period  of 
plasmacytoma development (i.e., the first 120 d after the injection of pristane). 
Materials and Methods 
BALB/cAn lr female mice were used throughout. All of the mice were bred in our 
closed conventional colony, and the induction experiments were carried out in the same 
1  Abbreviations  used in this paper:  MPO,  myeloperoxidase;  NSAID, nonsteroidal  antiinflammatory 
drug; PGE, -G, and -H. prostaglandins E, G, and H. 
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location. 40-60-d-old mice were given a single intraperitoneal injection of 0.5 or 1 ml of 
pristane (Aldrich Chemical Co., Milwaukee, WI) (8). Indomethacin (Sigma Chemical Co., 
St., Louis, MO) was put in solution at  10 g/ml in 100% ethyl alcohol and stored in the 
dark. The stock was diluted in tap water to a final concentration of 2,  10, or 20 t~g/ml. 
The drinking water was changed twice weekly. The mice were fed Purina Mouse Chow 
ad libitum. Controls were injected with pristane and given drinking water containing 
0.2% ethyl alcohol. 
Beginning at 120 d after the injection of pristane, the mice were examined every 14 d 
for the development of ascites. Ascitic fluid was obtained by paracentesis with a 25-gauge 
needle and the diagnosis of plasmacytoma was  made from Wright's-stained slides.  In 
experiment 2 (Table I), 20 of the mice in groups A and B alive at 300 d were autopsied 
and tissue sections were examined histologically for the presence of plasmacytomas. 
Histological studies were also done on mice given 0.5 ml i.p. pristane in experiment 4. 
These mice were killed by cervical  dislocation, and the tissues  were fixed in  Fekete's 
modified Tellyesniczky's fluid (70%  ethyl alcohol/formalin/glacial acetic acid, 20:2:1), 
and stained with hematoxylin and eosin. Multiple sections were taken from mesenteric 
tissues. To obtain peritoneal exudates, mice that did not have visible ascites were injected 
intraperitoneally with  10  ml  tissue culture  medium containing 10%  fetal calf serum. 
Cytofuge preparations were made in a  cytospin centrifuge (Shandon Southern Instru- 
ments, Inc., Sewickley, PA). 
Results 
Effect of Indomethacin on the Development of Plasmacytomas and Arthritis.  In- 
domethacin given continuously in the drinking water at a  concentration of 20 
~g/ml produced a dramatic reduction in plasmacytoma formation (Table I). Only 
4  plasmacytomas developed  in  180  mice (2.2%),  as compared with  64  in  183 
controls  (34.9%)  (Table  I,  groups  A  and  B).  During  the  time  of  maximal 
plasmacytoma development, i.e., from 150 to 240 d after the injection of pristane, 
most of the indomethacin-treated mice had a  healthy, vigorous appearance and 
did not develop  ascites.  A  few became  severely emaciated and  died,  and  the 
cause of death in these mice has not yet been determined. Mice treated with 10 
ug/ml indomethacin in the drinking water (Exp. 3, group C) also developed very 
few plasmacytomas, while  16% of the mice treated with 2 ~g/ml indomethacin 
developed ascites and plasmacytomas, indicating that  this  latter dose  of indo- 
methacin had only a mild inhibitory effect on plasmacytoma development. 
When indomethacin (20 ug/ml) treatment was begun at 60 d after the injection 
of pristane,  the incidence of plasmacytomas was also strikingly reduced.  Only 
four plasmacytomas among 50 mice were observed (group 1 C, Table I). Delaying 
the beginning of indomethacin treatment until day 160 produced a reduction in 
plasmacytoma development to 22% (group 1 D, Table I). 
A  high percentage of BALB/c mice given intraperitoneal pristane developed 
arthritis after a  latent period of 100 d, as observed in previous studies (9). The 
ankle joints were most frequently affected, and the process often appeared to be 
confined to these joints. Some of the mice, however, developed a  severe debili- 
tating arthritis  that  involved joints  in  both  upper  and  lower  extremities  and 
which  limited  mobility.  These  mice  often  became  emaciated.  Indomethacin 
partially reduced the incidence of arthritis (Table I), but clearly did not prevent 
its development. 
Effect of Indomethacin  on  Transplantable  Plasmacytomas.  When  105  to  106 
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TABLE  I 
Effect of lndomethacin on the Induction of  Plasmacytomas by the Intraperitoneal Injection of 
1.0 ml Pristane 
Concen-  lndomethacin  Percent  Percent plasmacytomas at day:  Total 
arthritis  No. 
Group  tration  Day  Day  at day  150  200  250  300  mice 
(ug/m[)  begun  ended  200 
1A  --  --  --  60  4  8  32  40  50 
1  B  --  --  --  42  4  18  28  40  50 
1 C  20  -7  300  22  0  0  0  0  50 
1 D  20  +60  300  40  0  2  6  8  50 
1 E  20  +160  300  36  6  8  12  22  50 
2  A  --  --  --  50  8  22  30  38*  50 
2 B  20  -7  300  18  0  0  2  5*  43 
2 C  20,10  -7,60*  300  21  1  1  2  4  47 
2 D  20  -7  120  26  0  4  5  10  50 
3 A  --  --  300  42  2  2  22  30  50 
3 B  20  -7  300  22  0  0  0  0  50 
3 C  l0  -7  300  12  0  0  2  7  50 
3 D  2  -7  300  38  2  4  10  16  50 
4  A  0  --  --  --  0  21  38  56  34 
4 B  20  -7  300  0  2  2  5  37 
All mice received an intraperitoneal injection ofpristane on day 0. Mice not receiving indomethacin 
were given diluent (0.2%  ethyl alcohol) in the drinking water with the exception of group 2 B, 
which received tap water. 
* Remaining mice at day 300 (20 in each group) were autopsied and peritoneal tissues were examined 
histologically for plasmacytomas; eight plasmacytomas were found in 2 A and two in 2 B. These 
tumors were not included in the day 300 incidence. 
* Group 2 C received 20 #.g/ml indomethacin for the first 60 d, followed by 10 ug/ml thereafter. 
0 Mice in groups 4 A and 4 B received a single injection of 0.5 ml pristane. 
intraperitoneally to a  normal  syngeneic host,  they usually do not grow progres- 
sively (5, 6). However, similar numbers  of cells almost always grow progressively 
when  transplanted  to  mice  that  have  received  an  intraperitoneal  injection  of 
pristane several days before  transplantation.  This  dependence  on  the  pristane- 
conditioned  peritoneal  environment  for  growth  is  usually  lost  after  a  single 
transfer (5). In the present study, we tested the ability of indomethacin  to inhibit 
the  growth  of four  primary  plasmacytomas in  transplant  recipients (Table  II). 
The  mice were  conditioned  with  three  different doses of pristane,  0.5,  0.2,  or 
0.1  ml.  Indomethacin  had  no  effect  on  the  growth  of  the  four  tumors  in 
conditioned mice. These results also indicate that indomethacin was not cytotoxic 
for plasmacytoma cells. 
Effect  of Indomethacin  on  the Development  of the Peritoneal  Inflammatory  Exu- 
date.  The  effects of indomethacin  on the  formation  of the peritoneal exudate 
were  studied  in  groups  of mice  on  days 67,  116,  145,  170,  and  180  after the 
intraperitoneal  injection  of  0.5  ml  pristane.  Preparations  of  the  peritoneal 
exudate  cells from each mouse were made  using the cytofuge, which permitted 
the examination of very large numbers  of well fixed and stained cells. The  total POTTER  ET  AL. 
TABLE  II 
Effect of lndomethacin on the Transplantation  of Primary Plasmacytoma Cells 
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Frequency of plasmacytoma occurrence in mice receiving: 
Tumor*  Control  Pristane only at dose (ml) 
pristane: 
Pristane plus indomethacin* at 
dose (ml) pristane 
0.5  0.2  0.t  0.5  0.2  0.1 
Myl 8-36  0/100  5/5  10/10  8/10  5/5  10/10  8/10 
Myl 11-52  1/10  5/5  10/10  9/10  5/5  10/10  10/10 
Myl 13-62  0/10  4/5  10/10  7/10  5/5  10/10  10/10 
Myl 2-7  1/10  5/5  10/10  10/10  5/5  10/10  I0/I0 
* Each mouse received  -105 viable primary plasmacytoma cells intraperitoneal]y.  Pristane-treated 
mice received an intraperitoneal injection of pristane 8 d before receiving the tumor cells. Controls 
received no pristane. 
* Indomethacin  treatment (20 ug/ml in drinking water) was begun 7 d before pristane injection. 
0 Data consist of fractions of which the denominator is the total number of mice, and the numerator 
is the number of mice with progressively growing plasmacytomas. 
TABLE  III 
Free Cells in Peritoneal Cavity 
Free cells (× 106) 
Days after 
pristane 
injection 
Pristane (0.5 ml)  Pristane (0.5 ml) plus 
indomethacin (20 #g/ml)** 
Total  Neutrophils  Total  Neutrophils 
mean (range)  mean (range)  mean (range)  mean (range) 
67  31.7 (21-34)  18.6 (14-22)  20.7 (9-46)  9.4 (5.6-18.6) 
116  19.9  (4-31)  11.6(2.4-17.7)  11.7(2.6-26.7)  5.8(1-12.0) 
145  17.6  (2-30)  6.4 (0.6-13.2)  11.9 (5.7-21.0)  5.t (1.2-8.3) 
170  22.2 (11-33)  4.5 (2.0-8.1)  13.7 (6-30)  4.9 (2.4-9.0) 
180  31.3 (17-62)  3.7 (0.2-11.8)  8.6 (3.5-11)  2.2 (1.0-3.1) 
Alcohol-water  Indomethacin (20 #g/ml) 
75  1.6(1.2-1.9)  0  (0)  1.4  (0.9-2.4)  0  (0) 
There were five mice in each group, except  alcohol-water and indomethacin controls,  which had 
only three mice, and the pristane-indomethacin  day 116, which had only four mice. The mice in this 
experiment were groups C (pristane), group D (pristane and indomethacin),  group E (alcohol and 
water), and group F (indomethacin) from Exp. 4 (see Table I). 
free peritoneal cells in mice injected with 0.5 ml pristane were consistently higher 
than observed in nonpristane controls. 
Three predominant cell types found in the exudates of pristane-injected mice 
were: (a) monocytic cells and macrophages, (b) neutrophils, and (c) lymphocytes. 
Because there were transitional stages with considerable morphological variation, 
particularly in the monocyte-macrophage series, it was often difficult to classify 
the cell types. Thus, the table indicates only the total numbers of polymorpho- 
nuclear leukocytes. Since neutrophils are not found or found only rarely in the 
peritoneal exudates of non-pristane-treated mice, their presence indicates an 
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in the total number of neutrophils in indomethacin-treated  mice but this did not 
constitute a striking difference. Free plasmacytoma cells were found in four mice 
from  the  pristane-only  group  (Nos.  101,  118,  141,  144) and  in  one pristane- 
indomethacin-treated  mouse (No.  137). The percentage of plasmacytoma cells 
ranged from 0.04 to 0.8% (Table IV). 
Histology of the Oil Granuloma.  Histological sections of peritoneal tissues from 
pristane-  or pristane-indomethacin-treated  mice that  were obtained  30-100 d 
after pristane injection showed no remarkable differences in the morphology or 
quantity of oil granuloma development. A more detailed study of the oil granu- 
loma was carried out on the groups of mice from which the peritoneal exudates 
were obtained (Table III). Tissue sections were obtained from five mice each on 
days  116,  145,  170,  and  181  (Table  IV).  Two general  differences in  the  oil 
granulomatous  tissues  from  pristane-  and  pristane-indomethacin-treated  mice 
were observed after day 116. First, there was less granulomatous tissue in many 
but  not  all  of the  mice  treated  with  indomethacin,  and,  very  often,  the  oil 
granuloma tissue in these mice showed less cellularity and inflammatory activity. 
It was difficult to quantitate  these  differences in  mesenteric  tissues,  but some 
assessment could be made  by comparing  oil  granuloma  formation  on  the  dia- 
phragm.  In  most  mice  given only pristane  the oil  granulomatous  process was 
extensive and appeared as large plaques of yellow, very hard, calcified tissue that 
TABLE  IV 
Summary of Histological Findings in the Mesenteric Oil Granuloma 
Day 
Pristane (0.5 ml)  Pristane (0.5 ml) plus indomethacin 
Mouse  EMM*  Plasma-  PCT  loci*  Free PCT  cells  f  Mouse  EMM  Plasma-  PCT  loci  Free  PCT 
No,  cytosis*  No.  cytosis  cells 
116  101  +  +  +  (m)  !  +  (0.04%)  103  -  -  - 
102  +  +  (m)  +  (m)  -  104  .... 
106  +  +  +  (m)  -  105  -  -  - 
107  +  +  -  -  109  +  -  - 
108  -  +  -  -  110  -  +  (2)  - 
145  116  -  +(m)  +(3) I  -  111  -  -  - 
117  +  +(5)  -  112  -  -  - 
118  --  +  (m)  +  (0.4%)  113  --  --  -- 
119  -  +  (m)  +  (5)  --  114  -  +  (2)  --  - 
120  -  +(1)  -  115  -  -  - 
170  132  -  -  -  130  -  -  - 
131  -  +(2)  -  127  -  -  - 
133  +  +  (5)  -  128  -  -  - 
134  -  +  +  (3)  -  129  -  +  -  - 
135  +  -  +  (m)  -  136  .... 
181  144  --  +  +  (4)  +  (0,29%)  146  --  +  (1)  --  -- 
143  -  +  +  (m)  --  145  --  --  -- 
142  --  +(m)  --  --  139  -  +(1)  --  - 
141  --  +  (m)  +  (0.8%)  138  --  +  -  -- 
140  +  +  +  (6)  --  137  --  +  (m)  +  (0.88%) 
Totals  16/20  2/20 
*  Focus of extramedullary  myelopoiesis that contains proliferating cells. 
* m, multiple. Numbers  in parentheses  represent  number  of loci. 
|  (-)  No plasmacytoma  ceils were seen by scanning the cytofuge preparations  that  usually contain  ~2.5  X  105 cells. 
I  Mouse  116  had a  large infiltrate that replaced a  polyp. POTTER  ET  AL.  1001 
immobilized the diaphragm. The indomethacin-treated mice had less diaphrag- 
matic infiltration and, in many of the mice, part of the diaphragm was virtually 
free of granulomatous tissue.  These  findings suggested that  prolonged indo- 
methacin treatment reduced the amount of granulomatous tissue by diminishing 
the inflammatory response to the oil and some of the associated complications, 
such as calcification and adhesion. This, however, was only observed in the tissues 
obtained after 116 d. 
A  second and  more significant difference in  oil  granuiomatous tissues  was 
related to plasma cell proliferation. Surprisingly, in  the mice studied between 
day  116  and day  180,  foci of proliferating plasma  cells that  morphologically 
resembled plasmacytomas were found in  16 of 20 pristane-treated mice (Table 
IV) while only 2 of 20 pristane-indomethacin mice had microscopic plasmacyto- 
mas.  These  foci  were  multiple  in  eight  of the  mice  (i.e.,  over  five  separate 
locations  in  the  peritoneum  were  involved)  and  resembled  typical  primary 
plasmacytomas. In the other eight mice, five fewer foci were found (Table IV). 
These probably represent some of the earliest histological evidence of plasma- 
cytoma development.  Many of these foci  did  not  appear  to  represent in  situ 
developing tumors but rather appeared to be deposits of cells that had originated 
elsewhere and  invaded  the  oil  granuloma  (Fig.  1).  Two  routes  of invasion, 
consistent with histology, were seeding on mesothelial surfaces or entry through 
blood  vessels.  Much  of the oil  granuloma  was organized into  small  polypoid 
structures  that  formed  on  the  mesenteric  peritoneal  surfaces  (Fig.  2).  The 
morphology and development of these polyps will  be described in  a  separate 
publication. Plasmacytoma infiltrates were found confined to single polyps, either 
as deposits on the surface or infiltrating the stalk of the polyp. 
Other forms of plasma cells were found in the peritoneal tissues. In most mice 
of both pristane- and pristane-indomethacin-treated mice, it  was easy to  find 
plasma  cells  scattered  throughout  the  oil  granuloma.  Also,  there  were  focal 
collections of plasma cells with uniform round nuclei and abundant cytoplasm 
(plasmacytosis) (Fig.  3).  Many of the foci were very small, containing as few as 
10 cells, others were larger. Lymphocytes were frequently found in association 
with plasmacytotic foci. A few plasmacytotic foci contained an occasional atypical 
plasma cell, suggesting a potential relationship of the plasmacytotic focus to the 
plasmacytoma. However, more detailed histological studies will  be required to 
establish such a relationship. Plasmacytosis appeared to be associated with active 
inflammation in the oil granuloma. 
Plasmacytoma cells were found in only five of the mice by scanning cytofuge 
preparations (Table IV). Thus, in the majority, the only evidence of a developing 
plasmacytoma was the presence of a  fixed focus of plasmacytoma cells. While 
this may appear to indicate that plasmacytoma development takes place in the 
peritoneal connective tissues, it is possible that some transformation steps occur 
in the peritoneal exudate population and that the foci represent seedings of these 
transformed cells on peritoneal surfaces. 
In addition to plasmacytosis and plasmacytoma, foci of extramedullary mye- 
lopoiesis were found frequently in 8 of 20 mice given pristane alone, while only 
one was observed in the pristane-indomethacin-treated mice. These loci usually 1002  INHIBITION  OF  PLASMACYTOMA  DEVELOPMENT  BY  INDOMETHACIN 
FIGURE  1.  Deposit of atypical large, intensely staining plasma cells from pristane-only mouse 
117 (Table IV) at day 145. Five small deposits were found in the mouse. The cluster shown 
in the figure was located near the base of a polyp. Hematoxylin and eosin, x  134. 
contained proliferating cells related to the myelomonocytic differentiation path- 
way. 
A  similar histological study was also performed on peritoneal tissues obtained 
from 20  mice in  each of groups 2  A  and  2  B  (Table I) at day 300.  These mice 
had not been diagnosed as having plasmacytomas by examination of the standard 
type of smears (see reference 8). In 8 of the 20 pristane-only mice, plasmacytomas 
were found,  while  two were found  in  the  pristane-indomathacin-treated  mice. 
The  degree  of infiltration  of oil  granulomatous  tissue  with  inflammatory cells 
was  much  less in  many of the  mice in  the  pristane-indomethacin  group,  giving 
the oil granulomatous tissue a  relatively acellular appearance. Furthermore,  few 
FIGUaE 2.  Focus  of atypical plasma cells that infiltrated a polyp from mouse 102 (Table IV) 
found at day 116. (A) Demarcated area occupied by the intensely staining atypical plasma cells. 
X 67. The focus probably occupies a polyp that has become adhered to adjacent polyps. (B) 
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FrGURE 3.  Oil granuloma showing a focus of plasmacytosis found at day 170 in pristane-only 
mouse  131  (Table IV). A cluster of plasma cells with uniform, relatively spherical nuclei and 
well-developed cytoplasm, surrounded by oil granulomas. Hematoxylin and eosin, x  134. 
plasma  cells  were  seen.  Histological  studies  of the  early focal  lesions  will  be 
described in a separate paper. 
Discussion 
The chronic treatment of BALB/c mice with indomethacin during the latent 
period of the induction of  plasmacytomas by pristane (minimum, 120 d) strikingly 
inhibited plasmacytoma formation. The inhibition  of pristane-induced plasma- 
cytoma development by indomethacin occurred despite the fact that the mice 
developed the characteristic oil granulomatous tissue, i.e., the microenvironment 
in which plasmacytomas develop. Indomethacin was effective when administered 
continuously or limited to just  the first  120  d  after the  injection of pristane. 
Further, indomethacin treatment could be delayed until 60 d after the pristane 
injection and still exert a strong inhibitory effect. The effectiveness  of the delayed 
treatment  suggested  that  plasmacytoma development  required  the  sustained 
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Histological studies revealed that during the first 116 d after the injection of 
1  ml  of pristane,  the  mice  that  were treated  continuously  with  indomethacin 
developed oil granulomas  and  peritoneal  exudates (Table III) that  were often 
difficult to distinguish morphologically from those seen in mice given only 1 mi 
pristane.  After 120 d, many of the indomethacin-treated  mice appeared to have 
less deposition of oil granulomatous tissue, particularly on the diaphragm.  The 
amount of oil granulomatous tissue in the mesentery has thus far been difficult 
to  quantitate.  After  116  d,  many  of the  indomethacin-treated  mice  also  had 
fewer inflammatory cells in the oil granuloma compared with those derived from 
mice treated only with pristane. 
Probably  the  most  striking  and  important  histological  difference  in  the  oil 
granulomas ofpristane- and pristane-indomethacin-treated  mice was the number 
of foci of plamacytoma cells in the oil granuloma.  Between days  116 and  180, 
foci of developing plasmacytomas were found in  80% of the pristane mice but 
only  10%  of "ndomethacin-pristane-treated  mice.  Plasmacytosis probably also 
occurred more frequently in the pristane mice but this was less easy to quantitate. 
Isolated plasma cells were scattered throughout oil granulomatous tissue in both 
groups of mice. It should be mentioned that a systematic study of the histogenesis 
of plasmacytomas has not yet been published. The findings in the present study 
are  some  of the  first  evidence  that  microscopic  plasmacytomas  precede  the 
appearance of overt plasmacytomas, i.e, plasma cell tumors that have spread over 
the peritoneum and are associated with free tumor cells in the peritoneum. 
The  incidence  of progressively  growing  plasmacytomas  in  BALB/c  7r  mice 
given a single injection of 0.5 ml pristane has been reported to be 22% (8). Thus, 
the  incidence  of microscopic  plasmacytomas  observed  in  the  pristane  group 
between  days  116  and  181  in  this  study  far  exceeds  the  number  of clinical 
plasmacytomas expected at this dose or which were observed in group 4 A (Table 
I). Thus, not all of these foci of neoplastic plasma cell proliferation will progress 
to a stage where the tumor can be detected by finding free plasmacytoma cells 
in the peritoneal exudate. 
The active oil granuloma also provided stimuli for the proliferation of cells in 
the myelomonocytic series.  Frequent  foci of extramedullary  myelopoiesis were 
found in  the  pristane  group and  only one  was found in  indomethacin-treated 
mice. The cells in these foci were in the myelomonocytic lineage.  This finding 
suggests that  indomethacin  treatment  could inhibit  the production  of essential 
growth factors required by myelopoietic stem cells, and raised the possibility that 
growth factors for plasma cells may also be curtailed. 
Biochemical and physiological actions of indomethacin  have been extensively 
studied;  its  most  specific and  powerful  action  is  as a  competitive  inhibitor  of 
prostaglandin synthetase EC 1.14.99.1  (10). Indomethacin competes with arach- 
idonic acid for one of the active sites on this enzyme.  Prostaglandin  synthetase 
has  at  least  two  active  sites:  a  fatty  acid  cyclooxygenase site,  which  converts 
arachidonic  acid  to  the  endoperoxide/hydroperoxide  intermediate  PGG2  in 
prostaglandin  biosynthesis, and a  peroxidase site that  reduces PGG2 to PGH2 
(11,  12). A  second action of indomethacin  is its ability to interact  with certain 
oxygen radicals  as a  direct  antioxidant  or scavenger.  Bodaness and  Chan  (13) 1006  INHIBITION  OF  PLASMACYTOMA  DEVELOPMENT  BY  INDOMETHACIN 
have shown that indomethacin can directly react with singlet molecular oxygen 
(~O2) and scavenge this highly reactive radical. In other studies, Pekoe et ai. (14) 
have  found  that  indomethacin  and  other  NSAID  compounds  can  scavenge 
oxidants derived from the neutrophil myeloperoxidase (MPO)-catalyzed reaction 
of  H202  and CI- that generates HCIO,  OH-,  and OH.,  presumably by some 
form of direct interaction with one or more of the oxidants. 
Mineral oils  or pristane injected into the peritoneal cavity are probably dis- 
persed into small droplets in the peritoneal fluid and phagocytosed by neutrophils 
and macrophages. Leak (15) has described the rapid deposition of fibrins and 
breakdown of fibrin  filaments after  the intraperitoneal  injection  of Freund's 
adjuvants and endotoxin; this raises the possibility that oil or pristane droplets 
cause the outpouring of proteins that could potentially opsonize pristane droplets. 
Histological sections show a  greater variety of configurations of macrophages 
and neutrophils around relatively large and variably sized oil drops.  Moreover, 
the  presence  of a  large  reserve  of oil  droplets  continuously  stimulates  the 
phagocytic system. There have been relatively few studies on the effects of oil 
injection on macrophage and neutrophil physiology, but it has been reported 
(16,  17) that oil-elicited peritoneal macrophages from both guinea pigs and mice 
are activated and can be stimulated by a variety of other nonphagocytic stimuli 
(e.g., phorbol esters) to produce superoxide anions. 
It is  likely that  the phagocytosis of oil  droplets and pristane by monocytes, 
macrophages, or neutrophils induces locally high  concentrations of toxic and 
potentially  mutagenic  oxygen  radicals.  This  would  potentially  occur  in  the 
peritoneal connective tissues (oil granuloma) or in the free space. Indomethacin 
then could reduce the generation of oxidants by: (a) blocking the formation of 
prostaglandin G2 (PGG2),  (b) neutralizing oxygen radicals derived from MPO- 
H202-CI-, and (c) directly interacting with IO2 and neutralize its effects. These 
actions would reduce the chance for exogenous oxygen radicals generated by 
phagocytes  to  attack  B  lymphocytes that  are  continuously  entering  the  oil 
granuloma or that may be in transit in the peritoneal space. 
It  is  tempting  to  speculate  that  oxygen  radicals  generated  by  continuous 
phagocytosis  of oil  might  play  a  role  in  the  formation  of  the  nonrandom 
chromosomal translocations that have been found in >95%  of plasmacytomas 
induced  by  mineral  oils  or  pristane  (see  18  and  19  for  references).  These 
translocations, rcptl2;15,  rcpt6;15, and an interstitial deletion in chromosome 
15, place the c-myc oncogene in a new context or disrupt its sequences. In both 
situations the c-myc gene is deregulated. The pathogenesis of these translocations 
are not understood but are thought to be facilitated by Ig gene rearrangement 
or by switching processes occurring on Ig gene-bearing chromosomes 12 and 6. 
The cause of chromosomal breaks is not known but could be enhanced nonspe- 
cifically by the availability of genotoxic substances.  Oxygen radicals have been 
implicated in the formation of chromosomal aberrations in other systems includ- 
ing lymphocytes (20-23).  It is not yet clear whether these oxygen radicals are 
generated endogenously in  lymphocytes or  are produced by  nonlymphocytic 
accessory cells. Indomethacin, however, has been found to inhibit the develop- 
ment of chromosomal damage in at least one of these situations (21). Three ways POTTER ET AL.  1007 
in which PG biosynthesis or prostaglandins may be implicated in tumor devel- 
opment are as  immunosuppressors, as  growth  regulators,  and as a  source of 
intracellular oxidants. 
Immunosuppression.  Actively phagocytosing macrophages release metabolites 
of arachidonic acid (24-26). One of these, prostaglandin E2, (PGE2), has a number 
of important  biological  actions:  (a)  suppression  of activation  of macrophages 
(27); (b) inhibition of Ia antigen on macrophages (28); (c) inhibition of mitogen- 
stimulated  proliferation  of T  suppressor  cells  (29,  30);  and  (d)  inhibition  of 
interleukin 2 (IL-2) production by human T  lymphocytes (31). In regions of high 
local PGE2 concentration, certain cell-mediated immune functions may be sup- 
pressed  (for  reviews,  see  32-34).  Immunosuppression  may be  a  factor  that 
permits developing plasmacytomas the chance to  escape immunosurveillance. 
Some evidence to support  this notion comes from Mandei and DeCosse (35), 
who showed that antithymocyte  serum accelerates ptasmacytomagenesis. Further, 
other types of antigenic tumors that produce large amounts of prostaglandins 
are  thought  to  induce  a  local  immunosuppression  that  can  be  relieved  by 
indomethacin (41, 42). 
Studies from other laboratories (36-39), have shown that transplantable plas- 
macytomas are potentially immunogenic to syngeneic hosts, and that they carry 
transplantation  rejection antigens. We have repeatedly observed that primary 
plasmacytoma cells do not grow progressively when transplanted into the peri- 
toneal cavities of normal BALB/c mice, yet these same cells grow progressively 
when introduced into peritoneal cavities conditioned by pristane.  Further, we 
previously (40) provided some evidence that pristane priming has some immuno- 
suppressive effects on established immunity. These results raised the possibility 
that pristane induces a microenvironment that suppresses tumor cell killing. We 
tested this hypothesis in the present study by transplanting primary plasmacyto- 
mas  to  pristane-conditioned  mice and  to  pristane-conditioned,  indomethacin- 
treated mice (Table II) and found that the "priming-dependent" plasmacytomas 
grew equally well in both pristane- and pristane-indomethacin-treated mice. We 
did not obtain evidence to support the notion that indomethacin relieves immu- 
nosuppression, although it could be argued that this finding was obtained with 
transplanted tumors and not with a developing neoplastic clone. 
Growth Regulation.  The effects of prostaglandins on B lymphocyte prolifera- 
tion are less well studied, but the findings reveal a  consistent picture.  Using a 
soft agar colony-forming assay to measure murine splenic B cell proliferation, 
Kurland and Moore (43) showed that 10  -1° to 10 -12 M PGE1 and PGE~ inhibited 
B  cell  colony  formation.  In  a  separate  study,  indomethacin  introduced  into 
cultures of lymph node  lymphocytes grown  in  the presence of macrophages 
increased the yield of B cell colonies in the presence of high macrophage/B cell 
ratios (44). Thus, indomethacin blocked the high exogenous production of PGE2 
from macrophages and permitted the  B  lymphocytes to  proliferate and form 
colonies. Using human cells, Lydyard et al. (45) showed that PGE2 promoted the 
development of pokeweed mitogen-stimulated plasma cell formation. PGE2 also 
inhibited the proliferative response of Staphylococcus aureus-stimulated  human 
B  lymphocytes (46).  These  findings  suggest  that,  if intraperitoneal  pristane 1008  INHIBITION  OF  PLASMACYTOMA  DEVELOPMENT  BY  INDOMETHACIN 
stimulates production of locally high concentrations of prostaglandins, the effect 
on surrounding B lymphocytes would inhibit proliferation and promote differ- 
entiation. 
Because indomethacin is a powerful inhibitor of prostaglandin synthetase, it is 
tempting  to  implicate  the  high  local  prostaglandin  formation  by  oil-induced 
inflammatory cells in plasmacytoma development. As discussed above, the prin- 
cipal way in which high levels of prostaglandins could affect plasma cell tumor 
development is by an immunosuppressive action. If this were the case, the growth 
of primary plasmacytoma cells that depend upon the inflammatory microenvi- 
ronment  (and  high  prostaglandin  levels)  for  growth  should  be  inhibited  by 
indomethacin. This was not found to be true. A  second possible prostaglandin 
mechanism is  stimulation  of proliferation  of B  lymphocytes, but the opposite 
effect was observed in in vitro studies reported elsewhere (43-46).  Thus, pros- 
taglandins have not yet been implicated in plasmacytoma development through 
their ability to mediate cellular proliferation. 
IntraceUular Oxidants.  Prostaglandin biosynthesis is a source of endogenous 
oxidants;  in  particular,  the  conversion  of PGG2  to  PGH2  by  prostaglandin 
synthetase liberates an oxygen radical (47, 48).  It has also been suggested (49) 
that  lipid  peroxides themselves may be  biologically active.  Tumor-promoting 
agents, such as the phorbol esters, activate protein kinase C and prostaglandin 
biosynthesis (50) and oxygen radicals (51).  The promoting effects of phorbol 
esters in epidermal carcinogenesis in mice can be partially blocked by indometh- 
acin (51). The promotion phase in epidermal carcinogenesis requires many weeks 
so there are temporal parallels between two-stage epidermal carcinogenesis and 
ptasmacytomagenesis. Although the role of tumor promoters in tumorigenesis 
has not been settled, they seem to induce multiple genetic changes in the cells 
which are essential to achieving the neoplastic state. Since intracellular oxidant 
production has been associated with clastogenic effects in lymphocytes (21-23), 
it  is  possible  that  the  nonrandom  translocation  in  plasmacytomagenesis, 
rcpt 12; 15, could be induced by oxidants liberated from phagocytes and absorbed 
by B cells or be generated endogenously by a product of the chronic inflammation 
in the oil granuloma. 
Summary 
Indomethacin given continuously in the drinking water (20 ug/ml) to BALB/ 
cAn zr mice during the latent period of pristane-induced plasmacytoma devel- 
opment dramatically reduced the plasmacytoma incidence from 34.9  to  2.2%. 
Additionally, indomethacin given from day 0  to  120 or begun as late as 60  d 
after a  single injection of 1.0  ml pristane was also highly effective in reducing 
the development of plasmacytomas. 
Indomethacin treatment did not prevent the formation of a peritoneal inflam- 
matory exudate or peritoneal oil granulomatous tissue, although it had a  mild 
inhibitory effect on the intensity of the cellular inflammation, particularly after 
extensive treatment of >100 d. Indomethacin treatment reduced the incidence 
of arthritis by 50%.  A major effect of indomethacin treatment was a reduction POTTER  ET  AL.  1009 
in the appearance of microscopic plasmacytomas that appear in the oil granuloma 
before  plasmacytomas can  be  detected by routine  sampling  of the  peritoneal 
exudate. Between days 116 and  181,  16 of 20 mice given 0.5 ml pristane were 
found  to  have  loci  of plasmacytoma  cells,  while  only 2  of 20  indomethacin- 
treated mice had loci-containing plasmacytoma cells: The number of mice with 
microscopic  foci in  the  pristane-treated  group  greatly exceeded  the  expected 
incidence of plasmacytomas (22%) at this dose ofpristane. The growth of primary 
plasmacytomas in transplant that is dependent on the pristane-conditioned peri- 
toneal environment was not inhibited by indomethacin treatment. The role of 
indomethacin in inhibiting plasmacytoma development was not established; two 
possibilities are that (a) it inhibits production of mutagenic and tissue destructive 
oxidants by inflammatory cells, and (b)  it inhibits prostaglandin  synthesis and 
intracellular production of oxidant biproducts. 
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